Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Evolus

Nasdaq:EOLS
Snowflake Description

High growth potential and fair value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EOLS
Nasdaq
$127M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • Evolus has significant price volatility in the past 3 months.
EOLS Share Price and Events
7 Day Returns
-8.7%
NasdaqGM:EOLS
5.6%
US Pharmaceuticals
-1.1%
US Market
1 Year Returns
-84.9%
NasdaqGM:EOLS
-7.4%
US Pharmaceuticals
-13.6%
US Market
EOLS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Evolus (EOLS) -8.7% -49.1% -67.3% -84.9% - -
US Pharmaceuticals 5.6% -6.8% -12.8% -7.4% 4.1% 1%
US Market -1.1% -17.8% -22.5% -13.6% 4.9% 16.3%
1 Year Return vs Industry and Market
  • EOLS underperformed the Pharmaceuticals industry which returned -7.4% over the past year.
  • EOLS underperformed the Market in United States of America which returned -13.6% over the past year.
Price Volatility
EOLS
Industry
5yr Volatility vs Market

Value

 Is Evolus undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Evolus to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Evolus.

NasdaqGM:EOLS Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 8 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:EOLS
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.69
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.691 (1 + (1- 21%) (61.65%))
1.018
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.02
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.018 * 5.44%)
7.28%

Discounted Cash Flow Calculation for NasdaqGM:EOLS using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Evolus is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:EOLS DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.28%)
2020 -70.21 Analyst x1 -65.44
2021 -16.94 Analyst x2 -14.72
2022 13.77 Analyst x2 11.15
2023 37.86 Analyst x2 28.58
2024 63.42 Analyst x2 44.64
2025 84.33 Est @ 32.97% 55.33
2026 104.23 Est @ 23.6% 63.74
2027 121.99 Est @ 17.04% 69.54
2028 137.18 Est @ 12.45% 72.90
2029 149.86 Est @ 9.24% 74.23
Present value of next 10 years cash flows $339.00
NasdaqGM:EOLS DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $149.86 × (1 + 1.74%) ÷ (7.28% – 1.74%)
$2,753.02
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $2,753.02 ÷ (1 + 7.28%)10
$1,363.65
NasdaqGM:EOLS Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $339.00 + $1,363.65
$1,702.65
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,702.65 / 33.73
$50.48
NasdaqGM:EOLS Discount to Share Price
Calculation Result
Value per share (USD) From above. $50.48
Current discount Discount to share price of $3.78
= -1 x ($3.78 - $50.48) / $50.48
92.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Evolus is available for.
Intrinsic value
>50%
Share price is $3.78 vs Future cash flow value of $50.48
Current Discount Checks
For Evolus to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Evolus's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Evolus's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Evolus's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Evolus's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:EOLS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-3.19
NasdaqGM:EOLS Share Price ** NasdaqGM (2020-04-02) in USD $3.78
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 24 Publicly-Listed Pharmaceuticals Companies 19.89x
United States of America Market PE Ratio Median Figure of 2,943 Publicly-Listed Companies 12.9x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Evolus.

NasdaqGM:EOLS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:EOLS Share Price ÷ EPS (both in USD)

= 3.78 ÷ -3.19

-1.19x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evolus is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Evolus is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Evolus's expected growth come at a high price?
Raw Data
NasdaqGM:EOLS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.19x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts
65.1%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.91x
United States of America Market PEG Ratio Median Figure of 2,006 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Evolus, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Evolus's assets?
Raw Data
NasdaqGM:EOLS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $2.37
NasdaqGM:EOLS Share Price * NasdaqGM (2020-04-02) in USD $3.78
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 182 Publicly-Listed Pharmaceuticals Companies 2.43x
United States of America Market PB Ratio Median Figure of 5,140 Publicly-Listed Companies 1.25x
NasdaqGM:EOLS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:EOLS Share Price ÷ Book Value per Share (both in USD)

= 3.78 ÷ 2.37

1.6x

* Primary Listing of Evolus.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Evolus is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Evolus's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Evolus has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Evolus expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
65.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Evolus expected to grow at an attractive rate?
  • Evolus's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • Evolus's earnings growth is expected to exceed the United States of America market average.
  • Evolus's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:EOLS Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:EOLS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 8 Analysts 65.1%
NasdaqGM:EOLS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 8 Analysts 29.4%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 27.5%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 12.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:EOLS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:EOLS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 307 96 61 7
2023-12-31 270 60 40 7
2022-12-31 231 42 18 8
2021-12-31 180 13 -21 8
2020-12-31 97 -60 -73 8
2020-04-03
NasdaqGM:EOLS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 35 -93 -90
2019-09-30 15 -89 -88
2019-06-30 2 -70 -73
2019-03-31 -43 -52
2018-12-31 -26 -47
2018-09-30 -15 -30
2018-06-30 -12 -21
2018-03-31 -10 -7
2017-12-31 -13 -4
2017-09-30 -14 -13
2017-06-30 -13 -14
2017-03-31 -14 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Evolus's earnings are expected to grow significantly at over 20% yearly.
  • Evolus's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:EOLS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below

All data from Evolus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:EOLS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 1.71 2.65 1.13 5.00
2023-12-31 1.17 1.98 0.35 6.00
2022-12-31 0.48 1.04 -0.46 6.00
2021-12-31 -0.42 0.34 -1.83 6.00
2020-12-31 -2.27 -1.93 -2.82 6.00
2020-04-03
NasdaqGM:EOLS Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -3.19
2019-09-30 -3.21
2019-06-30 -2.69
2019-03-31 -1.97
2018-12-31 -1.92
2018-09-30 -1.38
2018-06-30 -1.08
2018-03-31 -0.38
2017-12-31 -0.27
2017-09-30 -0.77
2017-06-30 -0.86
2017-03-31 -1.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Evolus will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Evolus's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Evolus has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Evolus performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Evolus's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Evolus does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Evolus's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Evolus's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Evolus's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Evolus Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:EOLS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 34.93 -90.03 113.59 3.97
2019-09-30 15.48 -87.97 95.53 4.74
2019-06-30 2.31 -72.81 71.84 6.02
2019-03-31 -51.68 43.20 7.16
2018-12-31 -46.87 29.15 6.49
2018-09-30 -29.98 18.57 6.51
2018-06-30 -20.78 12.52 6.00
2018-03-31 -6.64 7.07 5.72
2017-12-31 -4.48 4.82 6.69
2017-09-30 -12.67 4.09 8.16
2017-06-30 -14.20 3.93 9.76
2017-03-31 -17.98 5.69 11.82
2016-12-31 -20.07 7.03 12.61
2015-12-31 -31.11 9.88 20.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Evolus has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Evolus has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Evolus improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Evolus's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Evolus has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Evolus's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Evolus's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Evolus is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Evolus's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Evolus's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Evolus Company Filings, last reported 3 months ago.

NasdaqGM:EOLS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 79.46 73.51 129.80
2019-09-30 17.04 73.18 74.03
2019-06-30 41.18 72.86 99.93
2019-03-31 75.36 72.56 133.68
2018-12-31 84.38 0.00 93.16
2018-09-30 94.97 0.00 105.17
2018-06-30 37.94 0.00 43.59
2018-03-31 51.98 0.00 49.57
2017-12-31 -75.54 211.33
2017-09-30 -78.48 206.95
2017-06-30 -67.01 191.02
2017-03-31 -7.11 59.76
2016-12-31 -7.11 59.76
2015-12-31 12.00 46.17
  • Evolus's level of debt (92.5%) compared to net worth is high (greater than 40%).
  • Unable to establish if Evolus's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Evolus has sufficient cash runway for 1.3 years based on current free cash flow.
  • Unable to confirm if Evolus has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Evolus's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Evolus has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Evolus's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Evolus dividends.
If you bought $2,000 of Evolus shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Evolus's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Evolus's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:EOLS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 8 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1943 Stocks 3.1%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:EOLS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2020-04-03

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Evolus has not reported any payouts.
  • Unable to verify if Evolus's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Evolus's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Evolus has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Evolus's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Evolus afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Evolus has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Evolus's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
David Moatazedi
COMPENSATION $2,278,813
AGE 41
TENURE AS CEO 1.9 years
CEO Bio

Mr. David Moatazedi has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Moatazedi served as Senior Vice President of Medical Aesthetics at Allergan plc from April 2017 to May 6, 2018 and also served as its Division Head of the U.S. Medical Aesthetics Division, which includes facial aesthetics, plastic surgery and skin care products. He has worked in various leadership capacities within Allergan since March 2005, including as Vice President of Sales and Marketing of the U.S. Facial Aesthetics division from August 2014 to March 2016 and Vice President of Sales and Market of the U.S. Plastic Surgery Division from February 2013 to August 2014. Prior to Allergan, he served as a District Manager at Novartis Pharmaceuticals for the Dematology Division. He spent six years at Novartis Pharmaceuticals. He has been a Director of Obalon Therapeutics, Inc. since March 13, 2017. He has nearly twenty years of commercial and executive experience building multiple market leading brands. He also led several acquisitions for Allergan, including LifeCell™ for $2.9B and ZELTIQ® Aesthetics for $2.5B. Mr. Moatazedi holds an M.B.A. from Pepperdine University and a B.A. from California State University, Long Beach.

CEO Compensation
  • David's compensation has been consistent with company performance over the past year, both up more than 20%.
  • David's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Evolus management team in years:

1.7
Average Tenure
49
Average Age
  • The average tenure for the Evolus management team is less than 2 years, this suggests a new team.
Management Team

David Moatazedi

TITLE
President
COMPENSATION
$2M
AGE
41
TENURE
1.9 yrs

Lauren Silvernail

TITLE
CFO & Executive VP of Corporate Development
COMPENSATION
$1M
AGE
61
TENURE
1.9 yrs

Rui Avelar

TITLE
Chief Medical Officer and Head of Research & Development
COMPENSATION
$2M
AGE
57
TENURE
6.3 yrs

Alex Sabad

TITLE
Vice President of Operations
TENURE
1.5 yrs

Ashwin Agarwal

TITLE
Vice President of Finance
TENURE
1.6 yrs

Jeff Plumer

TITLE
Vice President of Legal

Crystal Muilenburg

TITLE
Vice President of Corporate Communications & Public Relations
TENURE
1.2 yrs

Mike Jafar

TITLE
Chief Marketing Officer
COMPENSATION
$4M
AGE
38
TENURE
1.8 yrs

Kurt Knab

TITLE
President of Sales
TENURE
1.5 yrs
Board of Directors Tenure

Average tenure and age of the Evolus board of directors in years:

2.3
Average Tenure
55.5
Average Age
  • The average tenure for the Evolus board of directors is less than 3 years, this suggests a new board.
Board of Directors

Vik Malik

TITLE
Chairman of the Board
COMPENSATION
$222K
AGE
56
TENURE
2.3 yrs

David Moatazedi

TITLE
President
COMPENSATION
$2M
AGE
41
TENURE
1.9 yrs

Bosun Hau

TITLE
Independent Director
COMPENSATION
$193K
TENURE
2.3 yrs

Robert Hayman

TITLE
Independent Director
COMPENSATION
$191K
AGE
60
TENURE
2.3 yrs

David Gill

TITLE
Independent Director
COMPENSATION
$202K
AGE
64
TENURE
2.2 yrs

Simone Blank

TITLE
Director
COMPENSATION
$186K
AGE
55
TENURE
2.3 yrs

Kristine Romine

TITLE
Independent Director
COMPENSATION
$181K
AGE
54
TENURE
2.3 yrs

Peter Farrell

TITLE
Independent Director
COMPENSATION
$248K
AGE
77
TENURE
0.8 yrs

Karah Parschauer

TITLE
Independent Director
COMPENSATION
$248K
AGE
41
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
15. Jun 19 Buy David Gill Individual 13. Jun 19 13. Jun 19 2,000 $13.65 $27,300
04. Jun 19 Buy Vikram Malik Individual 03. Jun 19 03. Jun 19 1,298,701 $19.25 $24,999,994
04. Jun 19 Sell ALPHAEON Corporation Company 03. Jun 19 03. Jun 19 -1,298,701 $19.25 $-24,999,994
31. May 19 Buy Kristine Romine Individual 29. May 19 29. May 19 2,090 $14.77 $30,863
31. May 19 Sell Lauren Silvernail Individual 31. May 19 31. May 19 -2,612 $13.53 $-35,352
22. May 19 Buy Kristine Romine Individual 20. May 19 20. May 19 40,562 $19.25 $780,819
22. May 19 Buy Simone Blank Individual 20. May 19 20. May 19 628,536 $19.25 $12,099,318
22. May 19 Sell ALPHAEON Corporation Company 20. May 19 22. May 19 -5,307,940 $19.25 $-102,177,845
X
Management checks
We assess Evolus's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Evolus has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Are Evolus, Inc. (NASDAQ:EOLS) Insiders Spending On Buying Shares?

For example, a Harvard University study found that 'insider purchases earn abnormal returns of more than 6% per year.' Check out our latest analysis for Evolus The Last 12 Months Of Insider Transactions At Evolus In the last twelve months, the biggest single purchase by an insider was when Chairman of the Board Vikram Malik bought US$25m worth of shares at a price of US$19.25 per share. … NasdaqGM:EOLS Recent Insider Trading, September 4th 2019 Evolus Insiders Bought Stock Recently We saw some Evolus insider buying shares in the last three months. … Insider Ownership of Evolus For a common shareholder, it is worth checking how many shares are held by company insiders.

Simply Wall St -

Can We See Significant Insider Ownership On The Evolus, Inc. (NASDAQ:EOLS) Share Register?

Insider Ownership Of Evolus The definition of company insiders can be subjective, and does vary between jurisdictions. … This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. … Private Company Ownership It seems that Private Companies own 33%, of the EOLS stock.

Simply Wall St -

Evolus, Inc.'s (NASDAQ:EOLS) Path To Profitability

In this article, I will touch on the expectations for EOLS’s growth and when analysts expect the company to become profitable. … Should the business grow at a slower rate, it will become profitable at a later date than expected. … Next Steps: There are too many aspects of EOLS to cover in one brief article, but the key fundamentals for the company can all be found in one place – EOLS’s company page on Simply Wall St.

Simply Wall St -

The Evolus (NASDAQ:EOLS) Share Price Is Down 47% So Some Shareholders Are Getting Worried

But in truth the last year hasn't been good for the share price. … Check out our latest analysis for Evolus Evolus hasn't yet reported any revenue yet, so it's as much a business idea as an actual business. … But with the share price diving 47% in the last year, it's probably fair to say that some shareholders no longer believe the company will succeed.

Simply Wall St -

What Type Of Shareholder Owns Evolus, Inc.'s (NASDAQ:EOLS)?

Generally speaking, as a company grows, institutions will increase their ownership. … Companies that used to be publicly owned tend to have lower insider ownership. … Evolus is a smaller company with a market capitalization of US$713m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Have Insiders Been Buying Evolus, Inc. (NASDAQ:EOLS) Shares This Year?

(NASDAQ:EOLS), you may well want to know whether insiders have been buying or selling. … In total, Evolus insiders bought more than they sold over the last year … We don't deny that it is nice to see insiders buying stock in the company

Simply Wall St -

Can You Imagine How Chuffed Evolus's (NASDAQ:EOLS) Shareholders Feel About Its 110% Share Price Gain?

Note that businesses generally develop over the long term, so it the returns over the last year might not reflect a long term trend. … Investors will be hoping that Evolus can make progress and gain better traction for the business, before it runs low on cash. … With the share price up 110% in the last year, the market is seems hopeful about the potential, despite the cash burn

Simply Wall St -

Can We See Significant Institutional Ownership On The Evolus, Inc. (NASDAQ:EOLS) Share Register?

(NASDAQ:EOLS), then you'll have to look at the makeup of its share registry. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … institutions are noticeable on the share registry.

Simply Wall St -

Should You Take Comfort From Insider Transactions At Evolus Inc (NASDAQ:EOLS)?

Evolus Insider Transactions Over The Last Year. … Over the last year, we can see that insiders have bought 50.64k shares worth US$1.3m. … In total, Evolus insiders bought more than they sold over the last year

Simply Wall St -

What You Must Know About Evolus Inc's (NASDAQ:EOLS) Major Investors

I am going to take a deep dive into Evolus Inc’s (NASDAQ:EOLS) most recent ownership structure, not a frequent subject of discussion among individual investors. … The impact of a company's ownership structure affects both its short- and long-term performance. … The effect of an active institutional investor with a similar ownership as a passive pension-fund can be vastly different on a company's corporate governance and accountability to shareholders.

Simply Wall St -

Company Info

Description

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.

Details
Name: Evolus, Inc.
EOLS
Exchange: NasdaqGM
Founded: 2012
$127,491,972
33,728,035
Website: http://www.evolus.com
Address: Evolus, Inc.
520 Newport Center Drive,
Suite 1200,
Newport Beach,
California, 92660,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM EOLS Common Stock Nasdaq Global Market US USD 08. Feb 2018
DB EVL Common Stock Deutsche Boerse AG DE EUR 08. Feb 2018
LSE 0K16 Common Stock London Stock Exchange GB USD 08. Feb 2018
Number of employees
Current staff
Staff numbers
235
Evolus employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/03 02:39
End of day share price update: 2020/04/02 00:00
Last estimates confirmation: 2020/04/01
Last earnings filing: 2020/02/25
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.